A randomized controlled trial, or RCT, is a study in which participants are assigned by chance to receive one intervention or another, and outcomes are then compared between the groups. Random assignment is what distinguishes the design and what gives it its power: because allocation is determined by chance rather than by clinician judgement or patient preference, the groups should differ only by chance at the outset, and any subsequent difference in outcome can reasonably be attributed to the intervention.

This is why the RCT is treated as the reference standard for evaluating whether a treatment works. It is not, however, suitable for every question, and a poorly conducted RCT can be less informative than a well-conducted observational study.

What Problem Does Randomization Solve?

If clinicians choose which patients receive a new treatment, their choices will reflect clinical judgement: perhaps healthier patients are given the more demanding regimen, or sicker ones are given the newer option as a last resort. Either way, the groups differ before treatment begins, and outcomes will reflect those differences as well as the treatment. This is confounding.

Statistical adjustment can correct for confounders that have been measured. It cannot correct for those that have not been measured or thought of. Randomization is the only method that addresses both: over a sufficient number of participants, chance distributes every characteristic — recorded or not, known or not — approximately evenly between groups.

How Randomization Works

Generating the Sequence

Assignment is generated by a chance process, typically computer-generated. Alternating assignment, allocation by date of birth, or by day of the week are not randomization: they are predictable, and predictability permits manipulation.

Common Randomization Methods

  • Simple randomization assigns each participant independently, like a coin toss. Straightforward, but can produce unequal group sizes in smaller trials.
  • Block randomization randomizes within small blocks so that group sizes stay balanced as recruitment proceeds.
  • Stratified randomization randomizes separately within strata defined by important prognostic factors, such as disease severity or study site, ensuring balance on those factors.
  • Minimization allocates each participant so as to minimize imbalance across several prognostic factors simultaneously, with a random element retained.
  • Cluster randomization randomizes groups — clinics, schools, villages — rather than individuals, used where the intervention is delivered at group level or where contamination between individuals is likely.

Allocation Concealment

Allocation concealment means that the person enrolling a participant cannot know what the next assignment will be. Without it, a clinician who can foresee the next allocation may consciously or unconsciously delay or advance enrolment of particular patients, reintroducing exactly the selection bias randomization was meant to eliminate. Central randomization systems and sequentially numbered, sealed, opaque envelopes are standard mechanisms. Concealment operates before assignment; blinding operates afterwards.

Control Groups

The control group defines what the intervention is being compared against.

  • Placebo control. An inactive treatment matched in appearance and administration. Appropriate where no proven effective treatment exists, or where withholding one for the trial period would not cause serious harm.
  • Active control. An established treatment. Necessary where effective therapy exists, and the relevant question is usually whether the new option is better than, or not meaningfully worse than, current care.
  • Standard care control. Whatever a patient would ordinarily receive, used where care is individualized or the intervention is a service or programme.
  • Waiting-list control. Common in behavioural and psychological research, where participants receive the intervention after the study period.

The choice of control shapes what the trial can claim. Superiority over placebo says nothing about performance relative to existing treatment.

Blinding

Blinding, sometimes called masking, conceals group assignment from those who might otherwise be influenced by knowing it.

  • Single-blind: participants do not know their assignment.
  • Double-blind: neither participants nor the investigators delivering treatment know.
  • Triple-blind: outcome assessors or data analysts are also kept unaware.

Blinding matters most where outcomes involve judgement — pain, function, quality of life, symptom scales — and least for outcomes like all-cause mortality, which are hard to misclassify. Some interventions cannot be blinded: a surgical procedure, a physiotherapy programme, a device that is visibly different. In those cases, blinded independent outcome assessment provides partial protection, and trials should report where blinding was not possible rather than obscuring it.

Designing and Analysing an RCT

Prespecification

The protocol and statistical analysis plan are written before enrolment and specify the primary outcome, the analysis population, the statistical methods, and any planned interim looks. Prespecification prevents the outcome or analysis from being selected after the results are known, which would make apparently significant findings substantially less reliable.

Sample Size and Power

Sample size is calculated so the trial has a reasonable probability of detecting a difference large enough to matter clinically. Trials that are too small may miss real effects and, when they do reach significance, tend to overestimate effect size.

Intention-to-Treat Analysis

Intention-to-treat analysis includes all randomized participants in the group to which they were assigned, regardless of whether they completed or even received the assigned treatment. This preserves the comparability randomization created. Per-protocol analysis, restricted to adherent participants, answers a different question and can reintroduce bias, since adherence itself is often related to prognosis. Per-protocol results are best treated as supportive rather than primary, though in non-inferiority trials both analyses are usually examined because intention-to-treat can bias towards concluding non-inferiority.

Handling Missing Data

Participants withdraw, are lost to follow-up, or miss assessments. Substantial or unbalanced missing data threatens validity. Trials should report how much data were missing, why, and what assumptions the analysis made, usually with sensitivity analyses testing whether conclusions hold under alternative assumptions.

Interim Analyses and Stopping Rules

Many trials plan interim analyses reviewed by an independent data and safety monitoring board, with prespecified statistical rules governing early stopping for harm, for clear benefit, or for futility. Because repeated testing inflates the chance of a spurious positive, stopping boundaries are set conservatively. Trials stopped early for benefit tend to overestimate the size of the effect.

Variants of the Design

  • Parallel group: the standard form; each participant receives one assigned intervention throughout.
  • Crossover: each participant receives both interventions in a random order, serving as their own control. Efficient for stable chronic conditions, unsuitable where treatment is curative or has lasting effects.
  • Factorial: two or more interventions tested simultaneously in the same trial, allowing assessment of each and of their interaction.
  • Cluster randomized: groups rather than individuals randomized; requires analysis that accounts for correlation within clusters.
  • Stepped wedge: all clusters eventually receive the intervention, with the timing of rollout randomized. Used where an intervention will be implemented regardless.
  • Adaptive and platform: prespecified modifications during the trial, or multiple interventions compared against a shared control under a master protocol.
  • Pragmatic trials: conducted in routine care settings with broad eligibility and simple outcome ascertainment, prioritizing generalizability over tight experimental control.

Strengths and Limitations

Strengths

  • Controls confounding by both measured and unmeasured factors.
  • Supports causal rather than merely associational conclusions.
  • Prespecification and registration make the analysis auditable.
  • Provides the evidence base regulators require for authorization.

Limitations

  • Generalizability. Restrictive eligibility criteria can produce a study population unlike the patients who will receive the treatment.
  • Rare and late harms. Trials are rarely large enough or long enough to detect uncommon or delayed adverse effects; observational surveillance is needed.
  • Feasibility and ethics. Some exposures cannot be randomized. Harmful exposures cannot ethically be assigned, and some interventions are too entrenched or too resource-intensive to randomize.
  • Cost and duration. Large confirmatory trials are expensive and slow, which shapes which questions get asked and by whom.
  • Quality varies. Inadequate concealment, unblinded subjective outcomes, heavy attrition, or selective reporting can undermine any RCT.

Sources

  • CONSORT Statement — reporting guideline for randomized controlled trials
  • Cochrane Handbook for Systematic Reviews of Interventions — risk of bias domains
  • International Council for Harmonisation — E9 statistical principles for clinical trials; E10 choice of control group
  • U.S. Food and Drug Administration — guidance on adequate and well-controlled studies
  • European Medicines Agency — clinical trials guidance
  • World Medical Association — Declaration of Helsinki (use of placebo)
  • ClinicalTrials.gov — trial registration records